Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

2,509.9 1,493.2

Accumulated other comprehensive income 55.7 87.8

(Accumulated deficit)/retained earnings (1,140.1) 353.0

_________ ________

Total shareholders' equity 1,227.0 1,942.3

_________ ________

Total liabilities and shareholders' equity 4,330.1 3,326.4

_________ ________

Unaudited US GAAP results for the three months and year to December 31,

2007

Consolidated Statements of Operations

3 months 3 months 12 months 12 months

to to to to

December December December December

31, 2007 31, 2006 31, 2007 31, 2006

$M $M $M $M

________ ________ ________ ________

Revenues:

Product sales 661.3 427.6 2,170.2 1,535.8

Royalties 61.8 61.1 247.2 242.9

Other revenues 1.4 8.3 18.9 17.8

_______ _______ ______ _______

Tota
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... ANGELES , Aug. 27, 2014  Lisa Kulik ... years this July 4 holiday, thanks to a groundbreaking ... Ph.D., an internationally renowned clinician-researcher at the University of ... a 55-year-old Peoria, Ariz. resident ... robs its victims of sight. On June 2, she ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a new ... - A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds ... microelectronics to water treatment, but is graphene the ... the Graphene Opportunity Report, authored by Tim ...
(Date:8/27/2014)... SEATTLE , Aug. 27, 2014  ARCH ... venture firms investing in the development of seed ... its eighth venture fund closed with more than ... exceeded its $250 million subscription target by more ... Fund VIII shows the strength and potential of ...
(Date:8/27/2014)... After the boom of the energy ... beverage craze is going to be the stress relief ... use Stress Relief energy pattern which can be applied ... a beverage, including minerals, herbs and liquids. Stress Relief ... power into rapid recovery and helping to adapt more ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4
... Receive Funding, From Allied Minds to Commercialize Novel Technology for the ... ... Aliquots, BOSTON, July 2 Allied Minds, a pre-seed investment,corporation ... Development, and Northeastern,University announce the creation of CryoXtract Instruments, LLC, a ...
... levels as a possible ... predictor of clinical activity -, TORONTO, ... ("Lorus" or the "Corporation"), a biopharmaceutical company,specializing in the research ... cancer, today announced publication by,an Ohio State University (OSU) clinical ...
... Microfluidic Systems Inc.,(MFSI) announced today that it has ... of Microfluidic - Bioagent Autonomous Networked Detector,(M-BAND). This ... funded phases by the DHS,Science and Technology Directorate ... allow for low-volume production of automated,systems for extended ...
Cached Biology Technology:Investment Firm Allied Minds to Commercialize New Frozen Aliquotter Technology with Two Local Major Universities. 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 3Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 5Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 2Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 3
(Date:8/27/2014)... campaigns against trans-fats have largely succeeded in sidelining ... at sugar for its potential contributions to Americans, ... wrangling over the best way to assuage the ... in Chemical & Engineering News (C&EN), ... Society. , In the article, Stephen Ritter, a ...
(Date:8/27/2014)... a dreaded bacterium that can be found in both ... 28 persons in Denmark have been infected with ... have died. , The bacterium is notoriously difficult to ... adapt to changes in its surroundings, says Associate Professor ... from the Department of Biochemistry and Molecular Biology, she ...
(Date:8/26/2014)... at the University of Warwick have provided the ... occurring protein is linked to early signs of ... the research found that the absence of the ... cells in the nervous system. These changes were ... signs of dementia, including restricted learning and memory ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3Lack of naturally occuring protein linked to dementia 2
... , Mountain View, CA September 14, 2012 ... it will open its application programming interface (API) to ... by Mike Polcari, the company,s Director of Engineering, at ... September 16th. 23andMe,s open API is designed to allow ...
... Diego have developed a novel technology that can fabricate, ... of soft, biocompatible hydrogels. Near term, the technology could ... including stem cells, in the laboratory. Long-term, the goal ... regenerative medicine. For example, in the future, doctors may ...
... Conn., Sept. 13, 2012 /PRNewswire-iReach/ -- Global Information ... offer on personalized medicine, next generation sequencing (NGS) ... a bio/pharmaceutical and life sciences industry analyst firm ... ) Personalized Medicine: Companies, Trends and ...
Cached Biology News:23andMe opens its API to developers 2Nanoengineers can print 3D microstructures in mere seconds 2How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment 2How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment 3
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: